Is serum anti-Müllerian hormone (AMH) assay a satisfactory measure for ovarian reserve estimation? A comparison of serum and peritoneal fluid AMH levels

Kostrzewa, Marta; Głowacka, Ewa; Stetkiewicz, Tomasz; Grzesiak, Mariusz; Szyłło, Krzysztof; Stachowiak, Grzegorz; Wilczyński, Jacek R.

doi:10.17219/acem/121010

Cited by 9 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AMH is released by granulosa cells and theca cells already in the primordial follicle, albeit at low levels. A much higher expression of AMH, which is possible to measure in the blood, is observed in preantral and small antral follicles with a 2-4 mm diameter [13]. AMH expression is not observed in large antral follicles, although its trace expression is observed in a preovulatory follicle, though this is not possible to measure in the blood [11][12][13][14].…”

Section: Physiology Of Amhmentioning

confidence: 92%

“…A much higher expression of AMH, which is possible to measure in the blood, is observed in preantral and small antral follicles with a 2-4 mm diameter [13]. AMH expression is not observed in large antral follicles, although its trace expression is observed in a preovulatory follicle, though this is not possible to measure in the blood [11][12][13][14]. The role of AMH in folliculogenesis is based on inhibition of primary follicle recruitment through its paracrine effect and inhibition of selection from a pool of small antral follicles through gonadotropin recruitment [4,9].…”

Section: Physiology Of Amhmentioning

confidence: 97%

“…The serum AMH concentration reflects the ovarian follicle pool with a strong dependence on the number of antral follicles in the early follicular phase of the menstrual cycle [12][13][14]. Therefore, a low antral follicle count may result in low serum AMH levels.…”

Section: Physiology Of Amhmentioning

confidence: 99%

See 2 more Smart Citations

Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS

Rudnicka

Kunicki

Calik-Ksepka

et al. 2021

IJMS

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged women. It is characterized by chronic anovulation, hyperandrogenism, and the presence of polycystic ovary in ultrasound examination. PCOS is specified by an increased number of follicles at all growing stages, mainly seen in the preantral and small antral follicles and an increased serum level of Anti-Müllerian Hormone (AMH). Because of the strong correlation between circulating AMH levels and antral follicle count on ultrasound, Anti-Müllerian Hormone has been proposed as an alternative marker of ovulatory dysfunction in PCOS. However, the results from the current literature are not homogeneous, and the specific threshold of AMH in PCOS and PCOM is, therefore, very challenging. This review aims to update the current knowledge about AMH, the pathophysiology of AMH in the pathogenesis of PCOS, and the role of Anti-Müllerian Hormone in the treatment of this syndrome.

show abstract

Section: Physiology Of Amhmentioning

confidence: 92%

Section: Physiology Of Amhmentioning

confidence: 97%

See 1 more Smart Citation

Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS

Rudnicka

Kunicki

Calik-Ksepka

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…AMH secretion drops significantly before menopause due to follicular failure [12]. The levels of AMH in patients with PCOS are significantly correlated with the number of ovarian small follicles, which reflects the presence of an ovarian follicle pool in the early follicular phase of the menstrual cycle and is strongly dependent on the number of antral follicles [13][14][15]. Tata et al showed that AMH concentrations during pregnancy are two-to-three fold higher in women with PCOS as compared to women with no reproductive defects, and the severity of the reproductive dysfunction is positively correlated with AMH levels [11,16].…”

Section: Introductionmentioning

confidence: 99%

Insulin-like peptide 5 (INSL5) positively correlates with anti-Müllerian hormone (AMH) in women with the polycystic ovary syndrome: a case-control study

et al. 2022

View full text Add to dashboard Cite

Background Insulin-like peptide 5 (INSL5) is involved in both reproductive and metabolic processes in polycystic ovary syndrome (PCOS). This study aimed to evaluate the relationship between INSL5 and anti-Müllerian hormone (AMH). Methods A retrospective case–control study was conducted in a university-based reproductive centre between December 2019 and January 2021. We included 117 women with PCOS and 100 healthy subjects from Zhejiang Province. All subjects were divided into four groups (1st–4th) based on quartiles of serum INSL5 levels. Serum INSL5 concentration was assayed using an enzyme-linked immunosorbent assay. Results A significant direct association was observed between serum INSL5 and AMH levels in women with PCOS. The mean AMH level in the 1st–4th INSL5 level quartiles were 4.64, 5.20, 6.46, and 9.48 ng/ml, respectively (P < 0.001). After adjusting for age, body mass index, metabolic indices, and serum levels of oestradiol and total testosterone, AMH levels remained positively and significantly associated with INSL5 levels (P for trend < 0.001). The diagnostic value of AMH was better than that of INSL5. Conclusions INSL5 and AMH levels were significantly correlated and elevated in women with PCOS. INSL5 and AMH might be associated with increased androgen secretion and chronic anovulation in PCOS.

show abstract

“…Sometimes the serum level of anti-Müllerian hormone (AMH) is measured before and after surgery to estimate the ovarian reserve. In young women, especially subfertile women who want to have a baby, the serum AMH level is a valuable predictor of reproductive potential [ 6 ]. In terms of bleeding control during laparoscopic ovarian cystectomy, bipolar electrocoagulation is a traditional and easy method, but it is hard to avoid thermal damage to the normal ovarian tissue.…”

Section: Introductionmentioning

confidence: 99%

Preservation of the ovarian reserve and hemostasis during laparoscopic ovarian cystectomy by a hemostatic agent versus suturing for patients with ovarian endometriosis: study protocol for randomized controlled, non-inferiority trial (PRAHA-2 trial)

Lim

Park

Paik

et al. 2021

Trials

View full text Add to dashboard Cite

Background Endometriosis (EMS) can be implanted everywhere, especially in pelvic organs. EMS can be asymptomatic, but it can result in pelvic pain and infertility by inducing local inflammation and pelvic adhesion. The prevalence of EMS is about 10% in reproductive-age women and higher in women with pelvic pain or infertility. For young patients with ovarian EMS, laparoscopic ovarian cystectomy is effective in relieving pelvic pain and preventing local recurrence. However, there is a concern that the ovarian reserve would decrease after the operation because of the removal of a part of the normal ovarian tissue and thermal damage during hemostasis, which depends on the types of hemostasis such as bipolar electrocoagulation, suturing, and the use of a hemostatic agent. In this study, we aim to evaluate the protective effect for the ovarian reserve and hemostasis between a hemostatic agent and suturing during laparoscopic ovarian cystectomy for patients with ovarian EMS. Methods This study is a randomized controlled, non-inferiority trial, where a total of 90 patients with ovarian EMS will be randomly assigned to the experimental (hemostatic agent) and control (suturing) groups. In the control group, a barbed suture will be applied for hemostasis, whereas a hemostatic agent will be applied in the experimental group. If two methods are insufficient, bipolar electrocoagulation will be applied for complete hemostasis. As the primary endpoint, the reduction rate of serum anti- Müllerian hormone (AMH) levels reflecting the ovarian reserve will be compared between the two groups 12 weeks after surgery. As secondary endpoints, we will compare the reduction rate of AMH level 48 weeks after surgery, the time required to complete hemostasis, the success rate of hemostasis within 10 min, and adverse events associated with operation. Discussion We expect that the protective effect for the ovarian reserve and hemostasis may be comparable between the two methods, suggesting that a hemostatic agent may be preferred considering that it is easy to use during laparoscopic ovarian cystectomy. Trial registration ClinicalTrials.govNCT04643106. Registered on 22 November 2020

show abstract

Is serum anti-Müllerian hormone (AMH) assay a satisfactory measure for ovarian reserve estimation? A comparison of serum and peritoneal fluid AMH levels

Cited by 9 publications

References 0 publications

Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS

Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS

Insulin-like peptide 5 (INSL5) positively correlates with anti-Müllerian hormone (AMH) in women with the polycystic ovary syndrome: a case-control study

Preservation of the ovarian reserve and hemostasis during laparoscopic ovarian cystectomy by a hemostatic agent versus suturing for patients with ovarian endometriosis: study protocol for randomized controlled, non-inferiority trial (PRAHA-2 trial)

Contact Info

Product

Resources

About